- Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92:1885-1893.
- Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl 2): 43-47.
- Manning AP, Thompson WG, Heaton KW, et al. Towards a positive diagnosis of the irritable bowel. B Med J 1978; 2:653-654
- Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1-7
- Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterology International. 1989;2:92-95
- Agréus L, Svärdsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995;109:671-680
- Triadafilopoulos G, Simms RW, Goldenberg L. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci 1991; 36:59-64
- Sivri A, Cindas A, Dincer B, Sivri B. Bowel dysfunction in irritable bowel syndrome in fibromyalgia patients. Clin Rheum 1996; 15:283-286
- Prior A, Wilson K, Whorwell PJ, Faragher EB. Irritable bowel syndrome in the gynecological clinic. Survey of 798 new referrals. Dig Dis Sci 1989;34:1820-1824
- Francis CY, Duffy JN, Whorwell PJ, Morris J. High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. Dig Dis Sci 1997;42:404-407
- Longstreth GF, Preskill DB, Youkeles Y. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome. Dig Dis Sci 1990; 1285-1290
- Hahn BA, Kirchdoerfer LJ, Fullertons S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11:553-559
- Talley NJ, O’Keefe EA, Zinsmeister AR, Melton LJ. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology 1992;102:895-901
- Drossman DA, Li Z, Andruzzi E, Temple RD, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-1580
- Heaton KW, O’Donnell LD, Braddon FM, et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992, 102:1962-7
- Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors and health care utilization. Am J Epidemiol 1995;142:76-83
- Bazzocchi G, Ellis J, Meyer J, et al. Colonic scintigraphy and manometry in constipation, diarrhea and inflammatory bowel disease. Gastroenterology 1988;94:A29
- Bazzocchi G, Ellis J, Villaneuva-Meyer J, et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology 1990;98:686-693
- Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994; 106:45-50
- Taylor I, Basu P, Hammond P, Darby C, Flynn M. Effect of bile acid perfusion on colonic motor function in patients with the irritable colon syndrome. Gut 1980; 21:843-847
- Narducci F, Snape WJJ, Battle WM et al. Increased colonic motility during exposure to a stressful situation. Dig Dis Sci 1985; 30:40-44
- Whitehead WE Holtkotter B, Enck P et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-1192
- Mertz H, Naloboff, Munakata J et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52
- Trimble KC, Farouk R, Pryde A et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific evidence for a generalized disorder of gut sensitivity. Dig dis Sci 1995; 40:1607-1613
- Cook IJ, Van Eden A, Collins SM. Patients with irritable bowel syndrome have a greater pain tolerance than normal subjects. Gastroenterology 1987; 93:727-733
- Silvermann DHS Munakata JA, Ennes H, et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112: 64-72
- Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318:565-567
- McKendrick MW, Read NW. Irritable bowel syndrome – post salmonella infection. J Infect 1994; 29:1-3
- Weston AP, Biddle WL, Bhatia PS, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590-1595
- Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-82
- Gwee KA, Graham JC, McKendrick MW, et al. Psychological scores and persistence of irritable bowel after infectious diarrhea. Lancet 1996; 347:150-153
- Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome: a multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95:701-708
- Delvaux M, Denis P, Allemans H. Sexual and physical abuse are more frequently reported by IBS patients than by patients with organic digestive diseases or controls: results of a multicentre inquiry. Eur J Gastroenterol Hepatol 1997; 9: 345-352
- Jones VA, McLaughlan P, Shorthouse M, et al. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982; 2:1115-1117
- Nanda R, James R, Smith H, et al. Food intolerance and the irritable bowel syndrome. Gut 1989; 30:1098-1104
- Benghtsson U, Nilsson-Balknas U, Hanson LA, et al. Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms. Gut 1996; 39:130-135
- Hamm LR, Sorrells SC, Harding JP, et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling Rome criteria. Am J Gastroenterol 1999; 94:1279-1282
- Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94:2912-2917
- Thompson WG, Heaton KW, Smythe GT, et al. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol 1997; 9:689-692
- Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333:1-4
- Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984; 25:168-173
- Whorwell PJ, Prior A, Faragher EB. Hypnotherapy in irritable bowel syndrome. Lancet 1984; ii:1232-4
- Svedlund J. Psychotherapy in irritable bowel syndrome: a controlled outcome study. Acta Psychiatr Scand 1983;67:1-86
- Guthrie E, Creed F, Dawson D, Tomerson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991;100:450-457
- Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-283
- Chiotakakou-Faliakou E, Kamm MA, Roy AJ, et al. Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation. Gut 1998; 42:517-521
- Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systemic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-147
- Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8:499-510
- Evans PR, Bak Y-T, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1996; 10:787-793
- Washington N, Ridley P, Thomas E, et al. Mebeverine decreases mass movements and stool frequency in lactulose –induced diarrhoea. Alimeth Pharmacol Ther 1998; 12:583-588
- Daly J, Bergin A, Sun WM, Read NW. Effect of food and anti-colinergic drugs on the pattern of rectosigmoid contractions 1993
- Van Outryve M, Mayer S, Meeus MA, et al. A double blind cross-over comparison study of safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Phaem Ther 1995; 20:277-282
- Clouse RE, Lustman PJ. Antidepressant therapy in 138 patients with irritable bowel syndrome; a five year clinical experience. Aliment Pharmacol Ther 1994; 8: 409-416
- Cadau G, Pallotta N, Badiali D, Corazziari E. L’impiego degli antidepressivi triciclici a basso dosaggio nel trattamento dei disturbi funzionali del tratto gastrointestinale superiore ed inferiore. Neurogastroenterologia 1998; 4:16-20
- Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000; 46:522-526
- Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 1982;27:807-814.
- Cann PA, Read NW, Holdsworth CD, et al . Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984; 29:239-247
- Luman W, Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption: long-term outcome. Eur J Gastroenterol Hepatol 1995;7:641-645
- Scarpignato C, Pelosini I. Novel drugs for treatment of functional gastrointestinal disorders. In: Approach to the patient with chronic gastrointestinal disorders. Corazziari E, Ed; Messaggi srl, Milano, Italy 1999: pp429-474
- Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome. Gastroenterology 2000;118:463-468
- Emmanuel AV, Nicholls T, Roy AJ, et al. Prucalopride improves colonic transit and stool frequency in patients with slow and normal transit constipation. Gastroenterology 2000; 118: (Suppl. 2 pt 1):A846:4438
- Schikowski A, Mathis C, Thewissen M, et al. Dose-dependent modulation of rectal afferent sensitivity with 5-HT4 receptor partial agonist. Gastroenterology 1999;116:A643
- Müller-Lissner S, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relievs key symptoms of irritable bowel syndrome. Gastroenterology 2000; 118: (Suppl. 2 pt 1):A175:1000
- Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355:1035-10.40
- Stacher G, Weber U, Stacher-Jannotta G, et al. Effects of 5.HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial. Br J Clin Pharmacol 2000; 49:429-436
- Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 1999; 13 Suppl A:71A-75A1642
- Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Dig Dis Sci 1995; 40:2244-2248
|